GRI Bio, Inc. - GRI
About Gravity Analytica
Recent News
- 04.02.2025 - GRI Bio Announces Closing of $5.0 Million Public Offering
- 03.18.2025 - GRI Bio Participates in a Virtual Investor CEO Connect Segment
- 03.17.2025 - GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
- 02.19.2025 - GRI Bio Announces Reverse Stock Split
- 12.23.2024 - GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
- 12.06.2024 - GRI Bio to Participate in the Virtual Investor Closing Bell Series
- 11.21.2024 - GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
- 11.14.2024 - GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
- 11.14.2024 - GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
- 10.24.2024 - GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024